
Opinion|Videos|May 15, 2024
Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data
Michael Blaha, MD, discusses the efficacy and safety of novel targeted therapies for lowering LDL cholesterol and emphasizes the importance of long-term data in building patient confidence in this new treatment option.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Alpha-Gal Syndrome: Closing an Underrecognized Allergy Diagnostic Gap
2
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF
3
ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans
4
Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Phase 3 Trial
5































































